TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04060303

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perioperative surgical care
Description: The ENRICH-US Protocol includes perioperative counseling and education, maintaining euvolumia through limited perioperative fasting and limited intraoperative fluid resuscitation, early enteral intake and mobilization, limited use of opioids, and non-routine use of surgical drains and tubes. Elements span the pre-, intra-, and post-operative experience for patients and involve care coordination among surgery, anesthesia, and nursing providers. Though individually simple, the concomitant implementation of the combined elements results in a markedly improved patient care experience that mitigates the physiologic stress of surgery and hastens recovery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perioperative surgical care
Description: The ENRICH-US Protocol includes perioperative counseling and education, maintaining euvolumia through limited perioperative fasting and limited intraoperative fluid resuscitation, early enteral intake and mobilization, limited use of opioids, and non-routine use of surgical drains and tubes. Elements span the pre-, intra-, and post-operative experience for patients and involve care coordination among surgery, anesthesia, and nursing providers. Though individually simple, the concomitant implementation of the combined elements results in a markedly improved patient care experience that mitigates the physiologic stress of surgery and hastens recovery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perioperative surgical care
Description: The ENRICH-US Protocol includes perioperative counseling and education, maintaining euvolumia through limited perioperative fasting and limited intraoperative fluid resuscitation, early enteral intake and mobilization, limited use of opioids, and non-routine use of surgical drains and tubes. Elements span the pre-, intra-, and post-operative experience for patients and involve care coordination among surgery, anesthesia, and nursing providers. Though individually simple, the concomitant implementation of the combined elements results in a markedly improved patient care experience that mitigates the physiologic stress of surgery and hastens recovery.
Study: NCT04170153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1774
Description: M1774 will be administered orally throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1774
Description: M1774 will be administered orally throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1774
Description: M1774 will be administered orally throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1774
Description: M1774 will be administered orally throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1774
Description: M1774 will be administered orally throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1774
Description: M1774 will be administered orally throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered orally throughout the study.
Study: NCT04521413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFI-402411
Description: CFI-402411 is administered orally once daily. The starting dose is 80 mg/day for escalation arms and the recommended dose for the expansion arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFI-402411
Description: CFI-402411 is administered orally once daily. The starting dose is 80 mg/day for escalation arms and the recommended dose for the expansion arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFI-402411
Description: CFI-402411 is administered orally once daily. The starting dose is 80 mg/day for escalation arms and the recommended dose for the expansion arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFI-402411
Description: CFI-402411 is administered orally once daily. The starting dose is 80 mg/day for escalation arms and the recommended dose for the expansion arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFI-402411
Description: CFI-402411 is administered orally once daily. The starting dose is 80 mg/day for escalation arms and the recommended dose for the expansion arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be given at its labeled dose and schedule, 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be given at its labeled dose and schedule, 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks.
Study: NCT03657628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Strength training and moderate-intensity, aerobic exercise
Study: NCT04699591

Intervention type: DRUG
Group type: OTHER
Intervention: Domperidone
Description: Domperidone taken 4 times a day, dose based on body weight
Study: NCT04340505

Intervention type: DRUG
Intervention: Fluocinolone Acetonide
Description: Injection of fluocinolone acetonide implant will be injected as standard of care treatment for patients with active uveitis.
Study: NCT01218893

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Plasmodium falciparum challenge
Description: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum challenge
Description: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
Study: NCT03173560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: lenvatinib capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: lenvatinib capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: everolimus tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: everolimus tablets.
Study: NCT02444338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MitraClip
Description: Implantation of the MitraClip System for patients with chronic heart failure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard of care
Study: NCT03012399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosedation
Description: Undergo hypnosedation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Verbal Support
Description: Speak with min-body specialist
Study: NCT06591260

Intervention type: OTHER
Intervention: support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation
Description: Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.

Intervention type: OTHER
Intervention: support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation
Description: Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.

Intervention type: OTHER
Intervention: support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation
Description: Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.
Study: NCT02484391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6,8-Bis(benzylthio)octanoic Acid
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV
Study: NCT06585800

Intervention type: OTHER
Intervention: sample collection
Description: blood and/or tissue collection

Intervention type: OTHER
Intervention: sample collection
Description: blood and/or tissue collection

Intervention type: OTHER
Intervention: sample collection
Description: blood and/or tissue collection
Study: NCT02702492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-9274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-9274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-9274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-9274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-9274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-9274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-9274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-9274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-9274
Study: NCT01218893

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Malarone treatment
Description: When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Malarone treatment
Description: When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Malarone treatment
Description: When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
Study: NCT02702492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-9274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-9274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-9274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-9274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin ER

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin ER

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin ER

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin ER

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin ER

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT01218893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Malarone treatment
Description: When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
Study: NCT04071990

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FB-CBGT
Description: CBGT for OCD patients, with Involvement of family members (partner, parent, sibling, ...)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CBGT
Description: CBGT for OCD patients, without involvement of family members
Study: NCT03735875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT06589492

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measurement of MMP-9 and SIRT-1 levels in blood serum
Description: Measurement of MMP-9 and SIRT-1 levels in blood serum, Collection of 5 ml Blood samples
Study: NCT04593927

Intervention type: DRUG
Intervention: Mayzent
Description: There is no treatment allocation. Patients administered Mayzent by prescription that have started before inclusion of the patient into the study will be enrolled.
Study: NCT03606668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HTC Vive Virtual Reality (VR) system
Description: VR treatment will entail use of computer software designed to immerse participants and engage them in exercises. Software includes virtual painting, walking through vivid and calming settings, solving puzzles, among others.
Study: NCT03657654

Intervention type: OTHER
Intervention: No intervention: observational only
Description: No intervention: observational only
Study: NCT03630354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete supervised exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete supervised exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete unsupervised exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive instructional DVD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06706193

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty using CPE

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty using HXLPE
Study: NCT02768311

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neolix rotary system (continuous rotation system)
Description: Procedure: neolix rotary system
Study: NCT06706466

Intervention type: OTHER
Intervention: observational study
Description: Non-interventional
Study: NCT02768311

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: waveone rotary system (reciprocating system)
Description: Procedure: waveone rotary system

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hand files k-files
Description: Procedure: hand files k-files
Study: NCT01128374

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal Scaling and root planing
Description: Participants will be instructed to brush their teeth using the modified Bass toothbrushing technique; the use of interproximal hygiene aids such as proximal brush or dental floss will be included. A full mouth scaling and root planning will be performed in 2 appointments (2 hours each) with the use of local anesthesia (typically 2% lidocaine with 1:100,000 epinephrine). In the control group, this treatment will be performed after all the data and samples have been collected and will encompass the last 2visits. Periodontal scaling and root planning treatment has been defined by The American Academy of Periodontology (AAP) as the standard of care for patients with periodontal disease. An ultrasonic instrument, scalers and curettes will be utilized to remove calculus and obtain a smooth root surface. The experimental subjects will be appointed 1 week later to complete the scaling and root planning procedure
Study: NCT00261690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction
Description: Using virtual reality distraction during a procedure
Study: NCT01024517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0259 solution
Description: single oral dose, GLPG0259, 50 mg oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0259
Description: single oral dose, GLPG0259, 50 mg solid formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0259
Description: single oral dose, GLPG0259, 50 mg solid formulation
Study: NCT02438163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta Burst Stimulation
Description: During the first session, After determining the parameters of stimulation (stimulated target : part of the left motor cortex responsible for the contraction of the right first dorsal interosseous muscle ; Activity Motor Threshold (AMT) ; Intensity of Stimulation providing a Motor Evoked Potential (MEP) with an Amplitude of 1mV (MEP 1mV)), a Baseline consisting of 15 MEP (intensity MEP 1mV) is measured. Then each subjet receive a TBS protocol (cTBS or iTBS) (intensity of stimulation 80% of AMT). After receiving the stimulation, sets containing 10 MEP are regularly measured by each subject.~During a second session, the same protocol is done again with the other TBS stimulation (cTBS or iTBS) the subject didn't get during the first session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta Burst Stimulation
Description: During the first session, After determining the parameters of stimulation (stimulated target : part of the left motor cortex responsible for the contraction of the right first dorsal interosseous muscle ; Activity Motor Threshold (AMT) ; Intensity of Stimulation providing a Motor Evoked Potential (MEP) with an Amplitude of 1mV (MEP 1mV)), a Baseline consisting of 15 MEP (intensity MEP 1mV) is measured. Then each subjet receive a TBS protocol (cTBS or iTBS) (intensity of stimulation 80% of AMT). After receiving the stimulation, sets containing 10 MEP are regularly measured by each subject.~During a second session, the same protocol is done again with the other TBS stimulation (cTBS or iTBS) the subject didn't get during the first session.
Study: NCT00079417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Study: NCT01175954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period. Dose Adjustments allowed up to 400 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period.
Study: NCT02355080

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On-site bundled rapid HIV/HCV testing
Description: Participants will be offered bundled on-site rapid HIV and HCV testing with post-test counseling that addresses both sexual and drug use risk reduction, and linkage to care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care (SOC)
Description: Participants will receive the SOC for HIV and HCV testing at the study sites.
Study: NCT04539782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention
Description: Compare the effect of structured pelvic floor muscle training supported by physiotherapist post operation on POP on recurrence of symptoms or symptoms in a new compartment, quality of life and pelvic floor muscle function.
Study: NCT04318067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Description: Melatonin 3 mg is given ones a day - at bedtimes for 6 month
Study: NCT01478139

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LIFT-plug
Description: Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track and plug (LIFT-plug) procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LIFT
Description: Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure
Study: NCT00297232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Study: NCT00783900

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol, biatrial pacing
Description: Prevention, atrial fibrillation, cardiac surgery, biatrial pacing, metoprolol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol, biatrial pacing
Description: Prevention, atrial fibrillation, cardiac surgery, biatrial pacing, metoprolol
Study: NCT00079417

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infrared Laser Therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Iodine I-125
Description: Undergo radioactive therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radioactive therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ruthenium Ru-106
Description: Undergo radioactive therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT03991221

Intervention type: OTHER
Group type: OTHER
Intervention: Dental Exam
Description: Visual examination of the child oral cavity bi non-orthodontist experts and orthodontist expert

Intervention type: OTHER
Group type: OTHER
Intervention: Dental Exam
Description: Visual examination of the child oral cavity bi non-orthodontist experts and orthodontist expert

Intervention type: OTHER
Group type: OTHER
Intervention: Orthodontics consult
Description: Consultation with an orthodontics specialist if a malocclusion requiring early intervention is detected

Intervention type: OTHER
Group type: OTHER
Intervention: Call back at 6 month
Description: Telephone call back at six months of inclusion in the study if a malocclusion requiring early intervention is detected
Study: NCT00485979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: larotaxel (XRP9881)
Description: intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: larotaxel (XRP9881)
Description: intravenous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: intravenous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: intravenous administration
Study: NCT01580878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lotrimin Ultra®
Description: Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) applied twice daily for 7 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Butenafine Vehicle
Description: Butenafine Vehicle applied twice daily for 7 consecutive days.
Study: NCT00485979

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: intravenous administration